Kidney Cancer Breakthrough
FDA Approves Belzutifan Plus Pembrolizumab Combination for Advanced Kidney Cancer
Key Points
In LITESPARK-022, disease-free survival (DFS) was not reached in either arm at interim reporting, but reported landmark DFS rates favored the belzutifan+pembrolizumab arm: 12-month DFS 91.9% vs 85.2%, 24-month DFS 80.7% vs 73.7%, and 30-month DFS 75.8% vs 68.6%. Interim overall survival (OS) was similar between arms (median OS not reached; HR 0.78, p=0.1220), with 12-month OS 98.3% vs 98.6%, 24-month 96.2% vs 95.7%, and 30-month 95.6% vs 93.8%.
Trial eligibility details for LITESPARK-022 included patients with histologically confirmed clear cell RCC with no prior systemic therapy; surgery within 12 weeks prior to randomization; and an ECOG performance status of 0 or 1.
Merck’s belzutifan (Welireg) is a first-in-class hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor that works by blocking a key transcription factor involved in tumor growth, angiogenesis, and cellular adaptation to hypoxia—providing biological rationale for its use in RCC.
The FDA-recommended regimens include specific pembrolizumab dosing schedules: pembrolizumab 200 mg IV every 3 weeks or 400 mg IV every 6 weeks when used with belzutifan; and for Keytruda Qlex, pembrolizumab plus berahyaluronidase alfa-pmph at 395 mg/4,800 units SQ every 3 weeks or 790 mg/9,600 units every 6 weeks, each combined with belzutifan 120 mg orally once daily.
Safety messaging for clinicians emphasized a boxed warning for embryo-fetal toxicity tied to belzutifan; oncology nursing guidance also stresses close monitoring for anemia and hypoxia.
The FDA approved belzutifan (Welireg) combined with pembrolizumab (Keytruda) on June 12, 2026, as adjuvant therapy for adults with clear cell renal cell carcinoma at intermediate-high or high risk of recurrence after surgery. The decision, based on the phase 3 LITESPARK-022 trial, marks the first time a HIF-2α inhibitor has been paired with a PD-1 blocker in the adjuvant kidney cancer setting, cutting the risk of disease recurrence or death by 28% compared to pembrolizumab alone, according to Urology Times.
The trial enrolled 1,841 patients. Disease-free survival at 30 months was 75.8% for the combination versus 68.6% for pembrolizumab alone. Overall survival data remain immature, Pharmacy Times reported, meaning the full survival benefit is still unknown.
LITESPARK-022 Trial Data That Drove the Approval
The pivotal LITESPARK-022 trial hit its primary endpoint of disease-free survival at a pre-specified interim analysis. The hazard ratio was 0.72 (95% CI: 0.59–0.87; p=0.0003), meaning patients on the combo were 28% less likely to see their cancer return or die, according to Urology Times. Median DFS was not reached in either arm at the time of reporting.
Landmark DFS rates favored the combination at every checkpoint. At 12 months: 91.9% vs. 85.2%. At 24 months: 80.7% vs. 73.7%. At 30 months: 75.8% vs. 68.6%. Overall survival showed a trend in favor of the combo (HR 0.78) but did not reach statistical significance (p=0.1220), MedPage Today noted. Full OS results are still pending.
How Belzutifan's HIF-2α Blocking Mechanism Works
Belzutifan is a first-in-class HIF-2α inhibitor. In clear cell RCC, a faulty VHL gene causes HIF-2α — a protein that drives tumor growth and new blood vessel formation — to build up abnormally. Belzutifan blocks that protein directly. Pembrolizumab then helps the immune system attack the tumor. The two drugs hit the cancer from different angles at the same time, Pharmacy Times explained.
Dr. Toni K. Choueiri, lead investigator of LITESPARK-022 and director of the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute, said the approval "establishes this combination as a new adjuvant option for patients with ccRCC at increased risk of recurrence." He added: "Surgery alone is not enough — this provides a more effective strategy to reduce the likelihood of the cancer returning."
Dosing Options Now Include a Faster Subcutaneous Shot
The FDA approved two pembrolizumab regimens alongside belzutifan 120 mg daily. The first is standard IV pembrolizumab: 200 mg every 3 weeks or 400 mg every 6 weeks. The second uses Keytruda Qlex — a subcutaneous formulation of pembrolizumab plus berahyaluronidase alfa-pmph — given as a 1-to-2-minute injection instead of a 30-minute IV infusion, according to Medscape. Treatment continues for up to 54 weeks or until recurrence or unacceptable toxicity.
Keytruda Qlex doses are 395 mg/4,800 units every 3 weeks or 790 mg/9,600 units every 6 weeks subcutaneously. GuruFocus noted that analysts see the shift toward subcutaneous dosing as a key move by Merck to maintain market share ahead of IV pembrolizumab biosimilar competition.
Higher Toxicity Burden Demands Close Clinical Monitoring
The safety trade-off is real. Grade 3 or worse adverse events hit 52.1% of patients on the combination — compared to 30.2% on pembrolizumab alone. Anemia occurred at a grade 3+ rate of 12.1% in the combo arm versus just 0.4% in the control arm. Hypoxia affected 4.6% on the combo versus 0% on monotherapy, according to Urology Times.
Belzutifan carries a boxed warning for embryo-fetal toxicity — the most serious FDA safety label. Clinicians are advised to monitor patients closely for anemia and low blood oxygen levels, which may require dose pauses or supplemental oxygen. Some experts argue the added toxicity may not be justified for all intermediate-high risk patients, and suggest reserving the combo for the highest-risk groups, such as those with M1 no evidence of disease status, MedPage Today reported.
Sentiment
Mostly PositivePublishers
12
Articles
9
Reach
21
